头孢曲松预防院外心脏骤停后昏迷患者早期肺炎:一项先导性随机对照试验及耐药组评估(PROTECT)
该先导性随机对照试验纳入院外心脏骤停后昏迷、接受目标温度管理、入院时无肺炎临床诊断的幸存者,随机接受头孢曲松2 g或匹配安慰剂每12小时一次共3天。最终每组26例分析:早期肺炎在头孢曲松组10例(38%)、安慰剂组18例(69%),风险比0.57(95%CI 0.21-1.001,P=0.05)。开放标签抗生素使用在头孢曲松组14例(54%)、安慰剂组22例(85%),风险比0.64(95%CI 0.43-0.94);校正基线耐药基因丰度后,头孢曲松组获得ICU常用抗生素耐药基因显著更少(发病率比0.30,95%CI 0.13-0.70)。两组均未报告严重药物不良反应。作者认为该试验对头孢曲松预防早期肺炎的影响不确定。
要点
- 院外心脏骤停后昏迷、目标温度管理、入院无肺炎临床诊断者,头孢曲松2 g每12小时一次共3天,早期肺炎38% vs 安慰剂69%(RR 0.57,95%CI 0.21-1.001,P=0.05)。
- 头孢曲松组开放标签抗生素使用54% vs 安慰剂85%(RR 0.64,95%CI 0.43-0.94),多数为广谱抗生素(分别为93%和100%)。
- 校正用药前耐药基因丰度后,头孢曲松组获得ICU常用抗生素耐药基因显著更少(发病率比0.30,95%CI 0.13-0.70)。
- 两组均未报告严重药物不良反应。
- 作者认为该试验对头孢曲松预防早期肺炎的影响不确定。
适用人群与场景
- 院外心脏骤停后昏迷的幸存者,接受目标温度管理,入院时无肺炎临床诊断。
处置流程与药物剂量
- 头孢曲松2 g或匹配安慰剂,每12小时一次,共3天。
研究设计与关键结果
- 先导性随机对照试验:筛查411例,随机53例(13%),1例退出,最终每组26例分析。
- 主要终点早期肺炎(插管后≤4天,由设盲裁定者确认):头孢曲松组10例(38%)vs 安慰剂组18例(69%),风险比0.57(95%CI 0.21-1.001,P=0.05)。
- 开放标签抗生素使用:头孢曲松组14例(54%)vs 安慰剂组22例(85%),风险比0.64(95%CI 0.43-0.94);多数为广谱抗生素(分别为93%和100%)。
- 校正用药前耐药基因丰度后,头孢曲松组获得ICU常用抗生素耐药基因显著更少(发病率比0.30,95%CI 0.13-0.70)。
- 两组均未报告严重药物不良反应。
证据类型、等级与局限
- 证据类型:先导性随机对照试验及耐药组评估。
- 作者结论:该试验对头孢曲松预防院外心脏骤停后早期肺炎的影响不确定;头孢曲松与更少的开放标签抗生素使用和更少的ICU常用抗生素耐药基因获得相关。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该试验对头孢曲松预防早期肺炎的影响不确定,但头孢曲松与更少的开放标签抗生素使用和更少的ICU常用抗生素耐药基因获得相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Antibiotic prophylaxis following out-of-hospital cardiac arrest (OHCA) reduces early-onset pneumonia. However, it has an uncertain impact on mortality and noninfectious outcomes, with ongoing concerns about the subsequent development of antibiotic resistance.
RESEARCH QUESTION: Does prophylactic ceftriaxone reduce the incidence of early-onset pneumonia without increasing the acquisition of antibiotic resistance genes after OHCA?
STUDY DESIGN AND METHODS: Comatose survivors of OHCA treated with targeted temperature management without a clinical diagnosis of pneumonia at admission were randomized to receive ceftriaxone 2 g or matching placebo every 12 hours for 3 days. The primary outcome was early-onset pneumonia occurring ≤ 4 days following intubation confirmed by masked adjudicators. Abundance of antibiotic resistance genes recovered from rectal swabs before and after study drug administration were analyzed with metagenomic sequencing.
RESULTS: A total of 411 participants were screened; 53 (13%) were randomized to treatment, and 1 participant withdrew, leaving 26 in each group in the final analysis. Early-onset pneumonia was diagnosed in 10 (38%) participants receiving ceftriaxone and 18 (69%) participants receiving placebo (risk ratio, 0.57; 95% CI, 0.21-1.001; P = .05). Open-label antibiotics were administered to 14 (54%) participants receiving ceftriaxone and 22 (85%) receiving placebo (risk ratio, 0.64; 95% CI, 0.43-0.94); most of the antibiotics were broad-spectrum agents (93% and 100%, respectively). After adjusting for differences in abundance of antibiotic resistance genes prior to study drug administration, participants randomized to receive ceftriaxone acquired significantly fewer antibiotic resistance genes to frequently used antibiotics in the ICU compared with those randomized to receive placebo (incidence risk ratio, 0.30; 95% CI, 0.13-0.70). Serious adverse drug effects were not reported in either treatment group.
INTERPRETATION: This trial was inconclusive regarding the impact of ceftriaxone prophylaxis on reducing the incidence of early-onset pneumonia following OHCA. However, ceftriaxone was associated with less frequent administration of open-label antibiotics and reduced acquisition of antibiotic resistance genes to frequently used antibiotics in the ICU.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04999592; URL: www.
CLINICALTRIALS: gov.
参考来源
- Gagnon DJ, Burkholder KM, Weissman AJ, et al. Ceftriaxone to Prevent Early-Onset Pneumonia in Comatose Patients Following Out-of-Hospital Cardiac Arrest: A Pilot Randomized Controlled Trial and Resistome Assessment (PROTECT). Chest. 2025. PMID: 40885534. doi:10.1016/j.chest.2025.08.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。